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Abstract
Keratoconus is a progressive corneal thinning, ectatic condition, which affects vision. Recent advances in corneal
topography measurements has helped advance proper diagnosis of this condition and increased research and
clinical interests in the disease etiopathogenesis. Considerable progress has been achieved in understanding the
progression of the disease and tear fluid has played a major role in the progress. This review discusses the
importance of tear fluid as a source of biomarker for keratoconus and how advances in technology have helped
map the complexity of tears and thereby molecular readouts of the disease. Expanding knowledge of the tear
proteome, lipidome and metabolome opened up new avenues to study keratoconus and to identify probable
prognostic or diagnostic biomarkers for the disease. A multidimensional approach of analyzing tear fluid of patients
layering on proteomics, lipidomics and metabolomics is necessary in effectively decoding keratoconus and thereby
identifying targets for its treatment.
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Background
Keratoconus is a progressive, asymmetric corneal ectasia.
It is characterized by the thinning and protrusion of the
cornea leading to irregular astigmatism and myopia
thereby affecting the visual performance [1].
Clinical characteristics and diagnosis
The disease is clinically diagnosed by corneal thinning and
steepening along with the presence of iron oxide hemosid-
erin deposits in corneal mid periphery (Fleischer’s ring).
Around 50 % of subjects exhibit Vogt’s striae, which are
fine stress lines caused by stretching and corneal thinning
[2]. Although clinical signs are helpful for the diagnosis,
keratoconus is typically confirmed by corneal topography
or tomography [3]. Although keratoconus is bilateral, in
certain scenarios, the clinical and topographic signs are
present in only one eye (unilateral keratoconus) wherein
the other eye is then diagnosed as form fruste keratoconus
[4, 5]. The onset of the disease occurs at puberty and
progresses up to the third decade of life [6, 7]. Hence, a
severity grading has been proposed for keratoconus to
differentiate a normal eye from a keratoconic eye based
on the clinical signs and corneal topography indices [8, 9].
Keratoconus has been reported to affect 1 in 500 to 1 in
2000 individuals and has a greater prevalence in Asians
indicating the role of ethnicity [5, 10–16].
Causative factors
Both genetic and environmental factors contribute to the
disease pathology [17–19]. Although atopy, eye rubbing,
ocular allergies, Down’s syndrome and tapetoretinal de-
generation have been associated with keratoconus [13],
the etiology and pathogenesis still remains unclear. Des-
pite the association of various genetic loci in twin and
familial studies, [19] the general consensus remains that
the disease is polygenic and is dependent on ocular sur-
face and tear molecular expression changes [20].
Tear proteomics
Tear fluid has been an important source of information
in understanding ocular physiology [21]. A large number
of proteases and protease inhibitors have been identified
in tears [22]. Zhou et al., have identified over 1500
proteins in the tear fluid majorly involved in carbohy-
drate catabolism, proteolysis, protein transport besides
immune response and regulation of apoptosis [23]. Dis-
ease specific molecular signature from tear fluid analysis
can help in understanding the etiology of the disease
and to help in prognosis. In addition, tear fluid can serve
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as an optimal source of molecular targets for treating
ocular disease conditions [24].
In this review, we attempt to discuss, in a concise man-
ner, the molecular markers for keratoconus that have been
recently discovered and the importance of tear film as a
source of these biomarkers in understanding the etiopathol-
ogy as well as in prognosis of the disease.
Review
Structure of the tear film
Tear film is essential in maintaining ocular homeostasis
and monitoring ocular surface conditions [25]. The tear
fluid secreted by the lacrimal glands is a complex matrix
comprising of an inner mucin layer, middle aqueous
layer and the outer lipid layer and is composed of lipids,
proteins, peptides, proteases, protease inhibitors and
metabolites. The lipid layer provides lubrication, stability
to the tear film and plays a protective role by preventing
the cornea from drying and shields against pathogens
[22, 26, 27]. Tear fluid helps in nourishing the corneal
epithelium and anterior stroma by delivering nutrients
and metabolic products [28]. Constitution of the tear
film influenced by disease specific changes in the molecular
markers can be of diagnostic value.
Another facet of the tear fluid analysis is the lipidome.
Analysis of the tear fluid lipidome by Rantamaki et al.
shows polar lipids, and the majority of tear lipids being
phospholipids; the composition of tear lipids differs dis-
tinctly from those of the meibomian gland [29]. A more
recent and comprehensive analysis of the human tear
fluid identified more than 600 lipid species belonging to
17 major lipid classes [30]. Besides lipidomics, a metabo-
lome analysis of tears from healthy subjects using mass
spectrometry revealed 60 tear metabolites of different
classes [31].
Tear biomarker discovery
Tear fluid as a source of biomarkers
Proteins lipocalin (LCN), lysozyme (LYZ), lactoferrin (LTF),
serum albumin (ALBU), proline rich repeat proteins (PRR)
constitute the most abundant proteins in the tear fluid [32].
Inflammatory proteins were observed in tears of patients
on long term glaucoma medication [33] and tear fluid pro-
teins were also considered as a means for screening diabetic
retinopathy [34, 35]. Tear proteins have been reported to
be altered in patients with keratoconus with and without
contact lens wear when compared to controls [36]. Tear
composition has been shown to be altered in various
inflammatory diseases like dry eye syndrome (DES) [37],
keratoconus [38], primary open angle glaucoma [39] and
Grave’s ophthalmopathy [21, 40]. Tear fluid has been
studied as a source of biomarkers in the diagnosis of
systemic conditions such as breast cancer [41, 42], dia-
betes [43, 44], multiple sclerosis [45], and severe acute
respiratory syndrome (SARS) [46]. These reports high-
light the importance of tears not only for the study of
ocular conditions but also for readouts of systemic
conditions.
Similar to the tear proteome, the tear lipidome and
metabolome can also undergo changes in keratoconus as
observed in other ocular disease such as DES where
reduced levels of wax esters and saturated fatty acyl
moieties in 93 DES patients were observed [47]. Besides
lipids, the tear metabolome has also been studied to
understand disease pathology. Using nuclear magnetic
resonance (NMR) spectroscopy, levels of about 50
metabolites were found to be varying in the tears of 55
DES patients compared with healthy subjects [48]. Ad-
vances in technologies such as mass spectrometry and
NMR have helped in studying and understanding molecu-
lar changes in the tear proteome, lipidome and metabolome
relating to an ocular disease condition.
Maintenance and handling of tear fluid for biomarker
discovery
Storage and maintenance of the collected tear fluid
under proper temperature conditions is critical for
successfully discovering a biomarker. Tear fluid from
patients can be non-invasively collected either using a
glass capillary or Schirmer’s strip [49]. However, the
Schirmer’s strip method of collecting tears is consid-
ered the most effective with minimum discomfort to
the patient and is often part of the DES ocular surface
disease test that patients already undergo in the clinic.
Since tear composition is complex with various pro-
teolytic enzymes, cytokines, and metabolites, the tear
fluid should be stored at sub-zero temperatures i.e.,
−70 to −80 °C. A reduction in total tear protein
concentration was observed when stored at room
temperature for 4–8 h [50].
Biomarkers of keratoconus
Genetic risk factors/markers of keratoconus
Genetic variation is one of the factors influencing the
incidence of keratoconus [19]. Genetic predisposition
to keratoconus in familial and monozygotic twins has
been well established [51, 52]. Single nucleotide poly-
morphisms (SNPs) in hepatocyte growth factor RAB 3
GTPase activating protein 1 (RAB3GAP1), interleukin
1β (IL1B), cadherin 11 (CDH11), negative regulator of
ubiquitin like protein 1 (NUB1), collagen type XXVII
A1 (COL27A1) and lysyl oxidase (LOX) were identified
by genome wide association studies (GWAS) as risk
factors for keratoconus [53]. However, the molecular
functions associated with these SNPs are not well
understood. Gene expression signatures of keratoconus
have been reported and offer new insights into the
disease process [20].
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Gene and protein expression markers in cultured corneal
cells and patient corneas
Differential gene expression analysis in debrided corneal
epithelia of patients with keratoconus showed dysregula-
tions of LOX and collagens - collagen I alpha 1 (COLIA1)
and collagen IV alpha 1 (COLIVA1) and an elevated
expression of matrix metalloproteinase 9 (MMP9) [54]. A
positive correlation between the reduced collagen expres-
sion with clinical severity of keratoconus was observed
indicating their role in structural deformity in keratoconic
corneas [54]. These genes were also associated with
elevated inflammatory cytokine IL-6 in the corneal epithe-
lium and in the tears of keratoconus patients. However,
cyclosporine A (CyA) treatment of tumor necrosis factor
α (TNFα) stimulated corneal epithelial cells and inhibited
the expression of IL-6, TNFα and MMP9 [55]. Cultured
human keratocyte cells (HKCs) stimulated with three
different isoforms of transforming growth factor β (TGFβ
I-III) showed deregulation of SMAD6 and SMAD7, indi-
cating altered TGFβ signaling in the progression of kera-
toconus [56]. Similarly a significant reduction in levels of
alcohol dehydrogenase (class 1) betapolypeptide (ADH1B)
in cultured keratoconic corneal fibroblasts suggested its
possible role in keratoconus [57].
Reduced levels of beta actin, a protein essential for cell
survival and growth, along with human antigen R (huR)
was observed in keratoconic and normal corneas both at
the transcriptional and translational level suggesting the
deregulation of these molecules as a possible trigger for
keratoconus [58]. Similar reduction in gene expression
of beta actin and alpha enolase was also observed in
superficial keratoconus epithelial cells compared with
normal corneas, suggesting the degradation of these
proteins in keratoconus [59]. Nielsen et al. performed a
proteomic analysis using 2D-gel electrophoresis followed
by mass spectrometry from keratoconus patient epithe-
lia. Compared to controls, the patient epithelium overex-
pressed gelsolin (GSN), alpha enolase (ENOA), S100A4
and cytokeratin3 (KRT3), which suggests a plausible role
of these proteins in the pathogenesis of keratoconus [60]
while possibly associating the role of structural proteins
and enzymes in keratoconus. These molecules can act as
prognostic or diagnostic biomarkers and may aid in
treatment of the disease. A list of the molecular markers
identified in cultured corneal cells and human corneas
are summarized in Table 1.
The genomic studies thus far have remained inconclu-
sive in terms of a molecular explanation for the pheno-
types observed and do not strongly correlate with the
molecular expression data from patient corneas. However,
the gene and protein expression data from the keratoconic
cornea do show deregulation of important factors and
pathways such as collagen synthesis, inflammation, extra-
cellular matrix, structural genes, TGFβ pathway and Wnt
signaling, to name a few. However, in a clinic, it is diffi-
cult to obtain corneal tissue for diagnosis and molecu-
lar profiling. This makes profiling tears of patients an
attractive prospect.
Tear specific markers for keratoconus
Pre-selected/targeted protein markers (ELISA)
Keratoconus is associated with tissue degradation that
involves extracellular matrix remodeling, collagen defi-
ciency [54] and more recently, increased roles of pro-
inflammatory cytokines, cell adhesion molecules and
matrix metalloproteinases [61]. Enzyme linked immuno-
sorbent assay (ELISA) analysis of capillary collected tears
in 28 [61], 30 [62] and 94 [63] patients with keratoconus
in three different studies showed elevated levels of
inflammatory markers IL-6, TNFα and MMP9. Thus, a
variety of matrix metalloproteinases (MMP) -1, -3, -7,
-13, interleukins (IL) -4, -5, -6, -8, and tumor necrosis
factor (TNF) -α and -β are elevated in keratoconus tears
[64]. Studies also demonstrate higher gelatinolytic and
collagenolytic activities in keratoconus [65]. Hence, pa-
tients with elevated MMP9 levels, when treated with
0.05 % CyA for 6 months, showed improved corneal
topography characterized by reduced disease progres-
sion, localized flattening and low tear MMP9 [55]. In
another study where tears from 33 keratoconus patients
were analyzed by ELISA, secreted-frizzled related pro-
tein 1 (SFRP1), a protein associated with the Wnt signal-
ing pathway, was observed at lower levels compared to
age-matched controls, indicating a novel signaling pa-
thway alteration in keratoconus [66] (Table 2). Tear
cytokine analysis performed to determine the effect of
collagen cross-linking on tear fluid composition showed
alterations in the tear cytokine levels [67]. These discov-
eries have significant clinical importance in aiding the
Table 1 Summarized list of biomarkers in keratoconus
Biomarker Expression Tissue/Cells Technique/Method Ref










SMAD6 ↓ HKCs RT-PCR/WB 50
SMAD7 ↓
ADH1B ↓ Cornea Microarray/WB 51
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development of biomarker kits targeted towards the diag-
nosis, prognosis and treatment of keratoconus as in the
case of other ocular diseases such as DES. A tear MMP9
point-of-care detection kit was developed for the diagnosis
and management of pre-op and post-op inflammation in
DES [68]. Furthermore, pre-existing information based on
different experimental methodologies enhances the reli-
ability of pre-selected markers. The high specificity and
sensitivity of target specific biochemical assays make them
reliable and clinically relevant for detecting molecular
changes both in a qualitative and quantitative manner.
Mass spectrometry based protein markers
Mass spectrometric analysis for protein biomarkers has
a dual advantage of surveying the unknown species
thereby discovering novel molecular changes from a rep-
ertoire of proteins, and quantifying the changes in a
multiplexed manner [69]. Using a nano-LC tandem mass
spectrometry approach, tears of 44 keratoconus patients
were compared with 20 healthy controls that identified
the elevation of cytokeratins, matrix metalloproteinase 1
(MMP1) and mammoglobin B (SGB2A1) [70]. Addition-
ally, lipocalin (LCN), lysozyme C (LYZ), immunoglobulin
alpha & kappa (IGKA & IGKC) and precursors to
prolactin were deregulated in keratoconus [70]. Tear
analysis using a 2-DE/MS approach, identified zinc-α2-
glycoprotein (AZGP1), immunoglobulin kappa chain,
and lactoferrin (LTF) to be reduced in keratoconus [71].
Using complimentary proteomic approaches of 2DE and
LCMSE (mass spectral data acquired in a data- independ-
ent acquisition mode, MSE), Acera et al. have shown a
significant decrease in the levels of cystatins and a higher
tear lipocalin-1 in patients with keratoconus [38].
Moreover, Balasubramanium et al. demonstrated reduc-
tion in total tear protein in keratoconus patients [65].
Protein levels of gross cystic disease fluid protein-15/
prolactin-inducible protein (PIP) and zinc-alpha-2-
glycoprotein have been found to be elevated in tears of
36 patients by proteomic analysis, suggesting their applica-
tion as prognostic markers for keratoconus [72] (Table 2).
One of the major challenges in tear proteomics is the
wide dynamic range of tear proteins. As discussed earlier,
certain proteins [32] due to their high abundance, are able
to mask the identification of low abundant proteins. A
comparison of the levels of abundant proteins in tears and
serum showed tear fluid to be similar in its protein abun-
dance to serum [23]. Though fractionation by 2DE helps
in resolving the abundance and complexity, it is limited by
other factors such as protein isoelectric point and hy-
drophobicity [73]. A gel-free approach overcomes such
limitations and coupled with fractionation methods such
as cation exchange chromatography, it aids in resolving
sample abundance and complexity [23].
Metabolic changes as a consequence of disease can
also be diagnosed from tears. Tear metabolome analysis
by LCMS among 45 subjects in 3 clinically defined
groups (healthy, keratoconus patients with RGP lens and
keratoconus with no correction) identified 296 different
metabolites among which more than 40 metabolites
associated with glycolysis, gluconeogenesis and the urea
cycle showed significant changes in keratoconus tears
[74]. Thus, the changes in underlying molecular signal-
ing and secretion pathways due to keratoconus could be
disease specific, affecting numerous biological processes.
Metabolite analysis by targeted mass spectrometry per-
formed on 2D and 3D cultured human corneal kerato-
cytes (KCKs), human corneal fibroblasts (HCFs) and
HKCs detected about 150 metabolites, the majority of
which are involved in the oxidative stress pathway,
implying its importance in keratoconus [75].
Disease specificity of tear biomarkers
Tear proteins LYZ, LTF, LCN were also reported to be
downregulated in DES. Besides, tear cytokines IL -4, -5 and
-6, and TNFα, which were elevated in keratoconus, were
also shown to have similar expressions in DES [76, 77],
indicating certain similar molecular changes among the
two disease conditions. Hence, it is imperative to prac-
tice caution while considering tear molecular changes
as biomarkers for a specific disease. Albeit, recent stud-
ies have shown that matrix metalloproteinases MMP1
and 9, AZGP1, SFRP1, IGKC and cell adhesion mole-
cules ICAM-1 and VCAM-1 to be specifically regulated
in keratoconus [36, 71], indicating their probable ex-
clusive role in keratoconus. In addition, the reduced
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activity of LOX [54] and levels of SFRP1 [66] are
specific to the disease and highlight the molecular path-
ways that can be targeted for disease correction. Since
collagen cross-linking is the current surgical treatment
available for keratoconus [78], reduction in the natural
collagen cross linkers [54] is perhaps expected. The
molecular pathways leading to the elevation of collage-
nolytic factors [55] presents another attractive target
for therapy. Since these large sample studies [54, 63]
indicate a broad range in the expression of such factors,
it is imperative to tune future treatment modalities
based on specific molecular targets to the correct
pathways. This could be possible through tear-based
biomarker profiling.
It is now understood that inflammation is one of the
primary drivers of keratoconus [55, 61–63, 71], there-
fore, it is not surprising that some of the markers
between keratoconus and DES are similar. However, the
amplitude of the deregulation of these markers such as
IL6 and MMP9, in correlation with disease phenotype
can be distinct amongst the different disorders with in-
flammatory drivers. Large sample cohort studies [54, 63]
would further validate the role of these proteins as specific
and potential biomarkers for keratoconus. Therefore, ac-
cumulated information about these markers should be
considered for application in diagnosis e.g., elevated
MMP9 and IL6 [55] along with a reduction in markers
such as LOX, SFRP1 [54, 66] in tears can give a specific
diagnosis of keratoconus. Many of these factors are
deregulated at the corneal tissue (epithelium and stroma)
level as well as the tears, further validating their import-
ance as biological processes specific to this disease as
established by different groups.
With the advent of high throughput technologies such as
multiplex cytokine bead array [77] and quantitative mass
spectrometry by multiple reaction monitoring (MRM) as-
says, multiple candidate markers can be validated in a rela-
tively shorter time and over a larger cohort of patients.
Zhou et al. have demonstrated quantitation of 47 tear
proteins in a MRM assay [69]. Multiplexed validation
also establishes a unique molecular fingerprint of the
disease and a more appropriate way of diagnosing and
treating keratoconus.
Conclusions
Tear fluid as a source of biomarkers in ocular and sys-
temic conditions has been well studied and is shown to
have translational potential. Moreover, the non-invasive
way of collecting the tears makes it an optimal biological
fluid to study with minimal to no discomfort to the
patient. Studies performed on tear fluid in patients of
keratoconus provided insights into the pathology of the
disease and has revealed probable prognostic as well as
diagnostic biomarkers for the disease. More importantly,
the recent studies and data from tear analysis establishes
the definitive role of inflammation as a driver of corneal
collagen loss and deformity in keratoconus patients.
Elevated cytokines move in tandem with elevated matrix
degrading enzymes to reduce levels of collagens and
collagen crosslinking enzymes resulting in the disease.
We term this as “Keratoconus Inflammaxis”, a unique
molecular signaling fingerprint identified with this
disease and its related pathology. The advances in te-
chnology such as high resolution high sensitivity mass
spectrometry have enabled mapping of the tear fluid in
patients and also the heterogeneity of keratoconus
pathology. A multi-omics approach integrating data from
proteomics, lipidomics and metabolomics is the need of
the hour for studying tear fluid as an important source of
biomarkers in keratoconus to lead to effective prognosis
and treatment of the disease.
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